Triumvira snags $55M Series A to guide TAC technology to the clinic
Triumvira Immunologics wants to bring its T-cell antigen coupler (TAC) technology to the clinic early next year, and it plans on riding a $55 million Series A to get there.
The Austin, TX-based biotech announced the completion of its financing round on Thursday. And now president and CEO Paul Lammers says it’s “all hands on deck” to submit an IND for the company’s HER2-directed TAC for solid tumor patients. Lammers hopes the TAC will be ready for human testing in late Q1 of 2021.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters